{
    "nctId": "NCT06603987",
    "briefTitle": "Using CICS-1 and SPM-011 and \uff3b18F\uff3dFBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA",
    "officialTitle": "Phase I/II Basket Trial: Boron Neutron Capture Therapy (BNCT) Using CICS-1 and SPM-011 for Patients with Recurrent Solid Malignant Thoracic Tumors That Are Unresectable and Perceived Challenging to Treat with Standard Treatment",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Thoracic Solid Malignant Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Occurrence rate of dose-limiting toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent must be obtained from the subject.\n* Patients with histopathological diagnosed malignant tumor (except cutaneous angiosarcoma)\n* Measurable disease, as defined by RECIST v1.1.\n* Patients diagnosed with recurrent malignant tumors that are unresectable and perceived challenging to treat with standard treatment.\n* Patients with ECOG performance status score of 0 or 1.\n* Patients whose longest diameter sum of the lesions to be treated is 15 cm or less.\n\nExclusion Criteria:\n\n* Patients with active disease or active double cancers other than target lesions.\n* Patients with imaging findings that affect imaging evaluation of the tumor, such as ground-glass opacities\n* Patients who received radiation therapy exceeding 65 Gy as a prior treatment for the target lesion.\n* Any serious concomitant disease that precludes completion of the study treatment.\n* Patients with remaining complications of Grade 3 or higher related to prior radiation therapy in the irradiation field.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}